2018
DOI: 10.1016/j.cell.2018.07.033
|View full text |Cite
|
Sign up to set email alerts
|

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection

Abstract: SUMMARY Antibodies are promising post-exposure therapies against emerging viruses, but which antibody features and in vitro assays best forecast protection are unclear. Our international consortium systematically evaluated antibodies against Ebola virus (EBOV) using multidisciplinary assays. For each antibody, we evaluated epitopes recognized on the viral surface glycoprotein (GP) and secreted glycoprotein (sGP), readouts of multiple neutralization assays, fraction of virions left un-neutralized, glycan struct… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

5
246
2

Year Published

2018
2018
2021
2021

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 187 publications
(253 citation statements)
references
References 85 publications
(123 reference statements)
5
246
2
Order By: Relevance
“…The neutralizing activity of each mAb was evaluated in three separate neutralization assays, and the EBOV GP epitope targeted by each mAb was defined (Saphire et al, 2018). Importantly, the protective activity of each mAb was evaluated in a mouse postexposure challenge model, where ten BALB/c mice were infected with 100 plaque forming units of mouse-adapted EBOV followed by passive transfer of 100μg of a given mAb two days post-infection.…”
Section: Resultsmentioning
confidence: 99%
See 4 more Smart Citations
“…The neutralizing activity of each mAb was evaluated in three separate neutralization assays, and the EBOV GP epitope targeted by each mAb was defined (Saphire et al, 2018). Importantly, the protective activity of each mAb was evaluated in a mouse postexposure challenge model, where ten BALB/c mice were infected with 100 plaque forming units of mouse-adapted EBOV followed by passive transfer of 100μg of a given mAb two days post-infection.…”
Section: Resultsmentioning
confidence: 99%
“…Importantly, the protective activity of each mAb was evaluated in a mouse postexposure challenge model, where ten BALB/c mice were infected with 100 plaque forming units of mouse-adapted EBOV followed by passive transfer of 100μg of a given mAb two days post-infection. The mAb panel included both human and mouse Abs with varying neutralizing activity ranging from no activity to potent neutralizing activity, spanning a variety of epitopes across the EBOV GP, and showed variables levels of protection (Saphire et al, 2018). Of note, within the panel of mAbs, VIC 1-136 were generated prior to the 2013-2016 EVD epidemic, and included both mouse and human neutralizing and non-neutralizing mAbs, whereas VIC 137-171 were donated after the recent EVD epidemic, and many were selected specifically for their strong neutralizing activity and generated as human IgG1.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations